Literature DB >> 14758777

Onercept. Serono.

Spyros N Nikas1, Alexandros A Drosos.   

Abstract

Onercept is a recombinant human soluble p55 tumor necrosis factor binding protein under development by Serono for the potential treatment of a number of disorders, including Crohn's disease, psoriasis and psoriatic arthritis. In March 2002, phase II trials were ongoing for these indications, and in February 2003, Serono expected phase III trials in psoriatic arthritis to commence in the second half of 2003.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14758777

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  5 in total

1.  Population pharmacokinetics of onercept in healthy subjects.

Authors:  Sophie Glatt; Eliane Fuseau; Mauro Buraglio; Quyen T X Nguyen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

Review 3.  Psoriatic arthritis treatment: biological response modifiers.

Authors:  P J Mease; C E Antoni
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 4.  [Psoriatic arthritis].

Authors:  Edmund Cauza; Attila Dunky
Journal:  Wien Med Wochenschr       Date:  2006-11

Review 5.  Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Expert Opin Investig Drugs       Date:  2008-04       Impact factor: 6.206

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.